XOMA Initiates Phase 2a Clinical Trial With XOMA 052 in Patients With Rheumatoid Arthritis
04 mars 2009 08h00 HE
|
XOMA Corporation
BERKELEY, Calif., March 4, 2009 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA) today announced the initiation of a Phase 2a clinical study evaluating its product candidate XOMA 052, a potent monoclonal...
Icagen Successfully Completes Phase I Multiple Ascending Dose Clinical Trial of Senicapoc
09 juil. 2008 07h30 HE
|
Icagen, Inc.
RESEARCH TRIANGLE PARK, N.C., July 9, 2008 (PRIME NEWSWIRE) -- Icagen, Inc. (Nasdaq:ICGN) today reported that the Company successfully completed the Phase I multiple ascending dose clinical trial of...
Evotec's EVT 101 Well Tolerated in Four Week Higher Repeat Dose Safety Study
03 juil. 2008 04h33 HE
|
Evotec AG
HAMBURG, Germany, July 3, 2008 (PRIME NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (Nasdaq:EVTC) announced today top-line results of a double-blind, 4-week Phase Ib study with EVT 101, an orally active...
MediciNova Reports Clinical Results From Two-Year Phase II Clinical Trial of MN-166 in Multiple Sclerosis
07 avr. 2008 06h00 HE
|
MediciNova, Inc.
SAN DIEGO, April 7, 2008 (PRIME NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka...
Chelsea Therapeutics Reports Positive Preliminary Results From Phase Ib Trial of CH-1504
21 déc. 2005 09h35 HE
|
Chelsea Therapeutics
CHARLOTTE, N.C., Dec. 21, 2005 (PRIMEZONE) -- Chelsea Therapeutics International, Ltd. (OTCBB:CHTP) has successfully completed the Phase Ib trial of its leading drug candidate, CH-1504, an orally...